Get started

PFE

PFE - DAILY CHARTHi, today we are going to talk about Pfizer and its current landscape. Pfizer is poised to receive increasing attention from the market as relevant events are taking place. The American multinational pharmaceutical has unveiled that is raising its quarterly dividend from $0.36 to $0.38 per share, a 6% surge that combined with the FDA approval of its new prostate cancer drug can help Pfizer change its currently bad momentum. However, the Lower Drug Costs Now Act can hit the company if it becomes law, despite the lack of support from the Trump administration and Senate, an eventual approval would throw a bearish sentiment over the sector. Thank you for reading and leave your comments if you like. To have access to our exclusive contents, join the Traders Heaven today! Link Below. Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
NYSE:PFE
by Igor-Silva
MERCK IS DIRT CHEAP. $11 BILLION CANCER DRUG. SALES BOOMING!We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings. Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street Corruption at it's best! We took a long position at $82.00 several weeks ago. We feel the stock is worth at minimum, $150.00 all day long. KEYTRUDA alone, not counting any other products manufactured / developed by Merck, or any other divisions of Merck, is forecast to bring in over $11 Billion in sales. Holding for the almost 3% Dividend and for the stock price appreciation into the future. 250,000 LONG @ $82.00 Best of Luck Everyone!
NYSE:MRKLong
by UnknownUnicorn3159981
Pfizer (PFE) - Short Term BearishNot financial advice. Do your own research. The ideas shared here are the personal opinions of the BitDoctor team. Trade at your risk. Looking at a bearish setup for PFE. Likely will be some chop up here to clear some stops and cause the short term options to expire worthless. I'd be looking to take profit here if you haven't already and potentially look for a buy lower than we currently are or get some puts on this with a longer expiration if thats your thing. Looking like the next 2-3 weeks for this one. Trade safely friends! <3 -CE-
NYSE:PFEShort
by bitdoctor
Daily PFE forecast timing analysis by Supply-Demand strength21-Jun Investing strategies by pretiming NYSE:PFE Investing position about Supply-Demand(S&D) strength: In Rising section of high profit & low risk Supply-Demand(S&D) strength Trend Analysis: About to begin an adjustment trend as a upward trend gradually gives way to a slowdown in rises and falling fluctuations Today's S&D strength Flow: Supply-Demand(S&D) strength flow appropriate to the current trend. View a Forecast Candlestick Shape Analysis of 10 days in the future: www.pretiming.com (You can easily create a trading plan.) D+1 Candlestick Color forecast: RED Candlestick %D+1 Range forecast: 0.2% (HIGH) ~ -1.0% (LOW), -0.9% (CLOSE) %AVG in case of rising: 1.1% (HIGH) ~ -0.5% (LOW), 0.7% (CLOSE) %AVG in case of falling: 0.6% (HIGH) ~ -1.1% (LOW), -0.4% (CLOSE) Price Forecast Timing Criteria: Price forecast timing is analyzed based on pretiming algorithm of Supply-Demand(S&D) strength.
NYSE:PFE
by pretiming
PFE- Potential very low Risk:Reward swing trade incoming?Hello all. As you can see I've been all about the low risk, simple swing trades these days! I believe if PFE hits the first green zone and stays in the channel, this should be a simple trade within the channel. I believe it may hit at least it's previous high, putting this swing at 30% profit if executed properly. This would be a good one to just do a partial profit take, or let it ride to see where it ends up with a conservative trailing stop. The continued growth is obvious and well, they make Viagra, sooo.....
NYSE:PFELong
by infbp22
Pfizer: Steady buy in a volatile market. Target $48.Pfizer has been among the top stocks during this year's market correction. Recently it has been trading within a 1D Channel Up which just priced its Higher Low (RSI = 48.610, MACD = 0.230, highs/Lows = 0.0000). Assuming it will print an identical Higher High next on +3.60%, we have a long target of $48.00 by mid January. Note that Pfizer also packs a decent quarterly dividend (yields 3.1%). ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
NYSE:PFELong
by InvestingScope
PFE Covered StrangleIn May I'd sold a covered call on PFE for debt of 32.50 (expired). I'd also had 1 lot from a year ago at 34.76. (Adjusted cost basis for 2 lots @ 33.63 ) I sold 32/34 Sep strangle for 50c before earnings for break-evens at 31.50 & 34.50. Today's current 1SD range by Sep expiry is 32-35, highlighted orange above. Possible outcomes: 1) Ideally the stock will rally above 34, with 1 lot called away at 34 for a small 1% gain on the position and theoretical unlimited profit on the second lot. 2) It stays between the 32 & 34 strikes until expiry and collect the full $50 credit. Might not seem like much but by selling these against the stock each quarter could bring in an extra 6% annually. If you're good it can be done twice as often as that! 3) Stock drops > 3% below the put strike and I'm assigned another lot of shares at 32 which averages down my overall cost basis on the stock. 4) The entire market crashes and the stock falls to 0... I do like the fundamentals of PFE and am willing to make a longer term investment. CFRA gives the stock a current fair value of $33 and Trefis price estimate is $34.60. The stock currently yields a 3.9% dividend and currently has a free cash flow yield over 6%.
NYSE:PFE
by dime